Key predictions of this hypothesis have been subsequently verified, including the presence of EBV-infected B cells in the brain and meninges of MS patients (75, 95–97), decreased CD8+ T-cell immunity to EBV in MS (98), and the therapeutic efficacy of B-cell-depleting therapies such as ocrelizumab (99, 100). Here, CD8A is linked to myeloid sarcoma.